Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 6, 2010, Pages 604-610

  Daniels, Craig E ^a   Lasky, Joseph A ^b,l   Limper, Andrew H ^a   Mieras, Kathleen ^a   Gabor, Edith ^b   Schroeder, Darrell R ^a   Chapman, Jeffrey ^c   Nathan, Steven ^d   Selman, Moises ^e   Alex, Charles ^f   Lee, Augustine ^a   Ginns, Leo ^g   De Andrade, Joaode ^h   Noth, Imre ⁱ   Glassberg, Marilyn ^j   Lieber, Janice ^k   Lancaster, Lisa ^m   Nobel, Paul ^o   Pascoe, Stephen ⁿ   Duffy, Jo Ann ⁿ  

^a MAYO CLINIC   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d INOVA FAIRFAX HOSPITAL   (United States)

^e Instituto Nacional de Enfermo Respiradores

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g Massachusetts General   (United States)

^h UNIVERSITY OF ALABAMA   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j UNIVERSITY OF MIAMI   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^m VANDERBILT UNIVERSITY   (United States)

ⁿ Health Economics and Outcomes Research Head   (Switzerland)

^o Novartis Pharmaceuticals ^*

more..

Author keywords

Idiopathic pulmonary fibrosis; Imatinib; Pulmonary function testing; Tryosine kinase inhibitor

Indexed keywords

CARBON MONOXIDE; CORTICOSTEROID; IMATINIB; PLACEBO;

ADULT; AGED; ANEMIA; ANGINA PECTORIS; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; IDIOPATHIC DISEASE; INFECTIOUS PNEUMONIA; LEUKOPENIA; LIVER CARCINOMA; LUNG DIFFUSION CAPACITY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PANCREATITIS; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SUBDURAL HEMATOMA; SUDDEN DEATH; SYNCOPE; THORAX PAIN; TREATMENT DURATION; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

AGED; ANEMIA; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DYSPNEA; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HEMATOMA, SUBDURAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LEUKOPENIA; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RESPIRATORY FUNCTION TESTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77749324295     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200906-0964OC     Document Type: Article

References (33)

1. ATS. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-664.
2. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006;3:364-372.
3. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007;30: 835-839.
4. Keane MP, Strieter RM, Belperio JA. Mechanisms and mediators of pulmonary fibrosis. Crit Rev Immunol 2005;25:429-463.
5. Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005;172:417-422.
6. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, Jarai G. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008;599:44-53.
7. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002;38:S28-S36.
8. Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002;346:683-693.
9. Lozano E, Segarra M, Cid MC. Stimulatory autoantibodies to the PDGF receptor in scleroderma. N Engl J Med 2006;355:1278-1279, author reply 9-80.
10. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-1413.
11. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-1316.
12. Azuma M, Nishioka Y, Aono Y, Inayama M, Makino H, Kishi J, Shono M, Kinoshita K, Uehara H, Ogushi F, et al. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med 2007;176:1243-1250.
13. Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H, Izumi K, Sone S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005;171: 1279-1285.
14. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350: 125-133.
15. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stahler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit CareMed 2008;177:75-81.
16. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, Fatenejad S. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948-955.
17. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-816.
18. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176: 636-643.
19. Yamasawa H, Sugiyama Y, Bando M, Ohno S. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration 2008;75:350-354.
20. Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, Akata S, Aoshima M, Serizawa H, Ohyashiki K. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004;18:645-646.
21. Daniels CE, Yi ES, Ryu JH. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J 2008;32:170-174.
22. Xu J, Mora A, Shim H, Stecenko A, Brigham KL, Rojas M. Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. Am J Respir Cell Mol Biol 2007;37:291-299.
23. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Mopps B, Mericskay M, Gierschik P, Biessen EA, Weber C. SDF-1alpha/ CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res 2005;96:784-791.
24. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-2821.
25. Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 2006;62:97-112.
26. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
27. Flaherty KR, Andrei AC, King TE Jr, Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med 2007;175:1054-1060.
28. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-2242.
29. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-1047.
30. Ingram JL, Bonner JC. EGF and PDGF receptor tyrosine kinases as therapeutic targets for chronic lung diseases. Curr Mol Med 2006;6: 409-421.
31. Distler JH, Manger B, Spriewald BM, Schett G, Distler O. Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum 2008;58:2538-2542.
32. Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J 2008;32:232-235.
33. Grosios K, Wood J, Esser R, Raychaudhuri A, Dawson J. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm Res 2004;53:133-142.